Bharat Parenterals Ltd

AI

Bharat Parenterals Ltd

₹ 2,407 -1.40%
19 Nov 11:41 a.m.
About

Incorporated in 1992, Bharat Parenterals Ltd is in the business of manufacturing and marketing of formulations[1]

Key Points

Business Overview:[1]
BPL is a Gujarat-based WHO GMP & an ISO 10002: 2014, 9001: 2015 certified pharmaceutical company. It manufactures over 800 products spread over 20+ different categories including General Products, β-Lactum/ Cephalosporin Products, Formulations in the form of Tablets, Capsules, Liquid- orals, Ointments, Creams, Lotions, and most importantly Powdered Injections and small Volume Parenterals both in Ampoules and Vials.

  • Market Cap ₹ 1,659 Cr.
  • Current Price ₹ 2,407
  • High / Low ₹ 2,499 / 880
  • Stock P/E 1,338
  • Book Value ₹ 482
  • Dividend Yield 0.04 %
  • ROCE -1.87 %
  • ROE -2.54 %
  • Face Value ₹ 10.0

Pros

  • Company is expected to give good quarter

Cons

  • Stock is trading at 4.96 times its book value
  • Company has low interest coverage ratio.
  • Company has a low return on equity of -0.79% over last 3 years.
  • Company has high debtors of 159 days.
  • Promoter holding has decreased over last 3 years: -6.64%
  • Working capital days have increased from 100 days to 143 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
60 60 68 93 72 72 104 116 65 65 100 94 136
55 53 67 88 79 69 102 102 64 63 100 85 113
Operating Profit 4 7 1 4 -8 4 2 14 1 2 -1 9 24
OPM % 7% 11% 1.5% 4.8% -11% 5% 2.1% 12% 1.3% 2.7% -0.5% 9% 17%
3 1 3 3 4 3 2 1 4 1 4 1 3
Interest 1 1 1 3 3 3 4 4 3 3 3 2 3
Depreciation 2 2 4 9 9 9 9 9 9 8 9 9 9
Profit before tax 5 5 -1 -5 -15 -6 -8 3 -7 -8 -8 -2 14
Tax % 46% 33% 88% 85% 14% 43% 14% 134% 18% 17% -3% 138% 16%
2 4 -3 -9 -18 -8 -9 -1 -9 -10 -8 -4 12
EPS in Rs 6.05 6.50 -0.52 1.96 -11.50 -2.42 -6.86 11.94 -10.50 -6.37 -6.96 1.47 13.67
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 (S) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
119 124 111 137 220 228 205 212 218 261 340 345 395
108 114 105 124 191 200 179 183 198 234 337 330 362
Operating Profit 11 10 7 12 29 28 25 29 20 27 4 16 33
OPM % 9% 8% 6% 9% 13% 12% 12% 14% 9% 10% 1.1% 4.6% 8%
4 5 8 7 13 11 9 7 12 5 11 10 9
Interest 2 1 1 1 1 1 1 1 3 4 13 13 11
Depreciation 4 4 6 6 6 6 6 7 6 9 35 34 35
Profit before tax 9 9 7 13 35 33 27 28 24 19 -34 -21 -4
Tax % 15% 31% 8% 29% 39% 26% 25% 25% 33% 44% 29% 27%
7 6 7 9 21 24 20 21 16 11 -44 -27 -10
EPS in Rs 12.98 11.26 12.03 15.92 37.09 42.13 35.59 36.45 28.47 24.95 -18.33 -11.88 1.81
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 3% 4% -5% -8%

(S): Standalone figures, shown where consolidated figures are not available.

Compounded Sales Growth
10 Years: 11%
5 Years: 11%
3 Years: 17%
TTM: 11%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 123%
Stock Price CAGR
10 Years: %
5 Years: 46%
3 Years: 63%
1 Year: 120%
Return on Equity
10 Years: 7%
5 Years: 3%
3 Years: -1%
Last Year: -3%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 (S) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 6 6 6 6 6 6 6 6 6 6 7 7 7
Reserves 44 51 58 67 88 112 138 160 177 191 324 315 325
16 19 6 9 5 1 12 18 50 158 180 146 160
50 44 40 50 60 68 43 42 118 149 138 145 171
Total Liabilities 116 120 110 132 159 188 199 226 350 504 649 613 664
29 35 31 34 35 33 45 41 42 211 252 255 245
CWIP 0 0 0 0 1 12 0 26 99 25 31 35 36
Investments 0 0 1 1 1 0 43 11 0 0 5 6 62
87 85 79 98 121 142 111 148 209 268 360 317 320
Total Assets 116 120 110 132 159 188 199 226 350 504 649 613 664

(S): Standalone figures, shown where consolidated figures are not available.

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 (S) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
0 0 -2 6 20 14 24 -1 22 -5 -27 38
0 0 -2 -8 -9 -13 -43 -7 -78 -105 -137 9
0 0 -8 4 -4 -3 10 9 61 110 156 -47
Net Cash Flow 0 0 -11 2 7 -1 -8 2 4 1 -8 1
Free Cash Flow 0 0 -4 -2 12 -0 24 -40 -68 -108 -56 -1
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 0% 0% -8% 73% 107% 87% 123% 16% 150% 18% -444% 305%

(S): Standalone figures, shown where consolidated figures are not available.

Ratios

Consolidated / View Standalone

Mar 2015 (S) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 179 130 143 157 106 127 121 126 188 198 184 159
Inventory Days 55 62 70 60 59 71 61 56 100 142 132 162
Days Payable 188 171 168 110 83 104 71 64 136 137 136 122
Cash Conversion Cycle 47 21 45 107 82 93 111 118 152 202 180 199
Working Capital Days 58 8 64 78 73 89 106 148 91 81 76 143
ROCE % 17% 11% 18% 39% 31% 20% 17% 11% 7% -4% -2%

(S): Standalone figures, shown where consolidated figures are not available.

Insights

In beta
Mar 2025 Mar 2026
Varenyam Healthcare Field Force (Medical Representatives)
Count ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Varenyam Healthcare Hospitals Covered
Count ・Standalone data
BPL Standalone Dossiers Submitted
Count ・Standalone data
BPL Standalone General Block Capacity Utilization
% ・Standalone data
BPL Standalone New Product Registrations
Count ・Standalone data
BPL Standalone Order Book
INR Crore ・Standalone data
Innoxel Cumulative Deals Signed (Out-licensing + CMO/CDO)
Count ・Standalone data
Varenyam Healthcare Active Brands
Count ・Standalone data
Varenyam Healthcare PCPM (Per MR per Month)
INR Lakh ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
73.84% 73.27% 73.27% 65.35% 67.20% 67.20% 67.19% 67.19% 67.19% 67.17% 67.20% 67.20%
0.00% 0.00% 0.00% 0.08% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11%
0.01% 0.01% 0.01% 0.57% 0.54% 0.54% 0.54% 0.54% 0.54% 1.07% 1.38% 1.29%
26.15% 26.72% 26.72% 33.98% 32.16% 32.15% 32.16% 32.16% 32.17% 31.65% 31.31% 31.40%
No. of Shareholders 2,3972,4972,7082,7483,1163,1773,2313,2053,1723,0953,0593,709

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls